ERBB2 and triple-negative breast carcinoma: Wang et al. found that the diffuse decrease pattern in HR+/HER2- and stable disease in HER2+ and triple-negative breast cancer could serve as indicators of the response to NAC in their stratified analysis by HR/HER2 subtype [38].